<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drug design, drug delivery and technologies</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Pharma industry faces long haul to get return on investment from AI</title>
      <description>
        <![CDATA[Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of companies sort of get this big excitement about AI, but then when you look at how much ROI they get, it’s actually very little. And that’s because the workflow and the process, end-to-end, isn’t mapped to really understand where AI can truly make an impact,” said Laura Matz, chief science and technology officer at Merck KGaA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730716</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730716-pharma-industry-faces-long-haul-to-get-return-on-investment-from-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-drug-development-illustration.webp?t=1776978683" type="image/jpeg" medium="image" fileSize="1049020">
        <media:title type="plain">Glowing neural network inside a transparent capsule surrounded by a large language model</media:title>
      </media:content>
    </item>
    <item>
      <title>Detecting the invisible: minimal residual disease at AACR 2026</title>
      <description>
        <![CDATA[Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision. As increasingly sensitive technologies reveal traces of cancer that persist after therapy, MRD is emerging as both a biological challenge and a clinical opportunity, especially as new data illuminate its complexity across hematologic and solid tumors. This topic was addressed at the 2026 American Association for Cancer Research (AACR) annual meeting. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730633</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730633-detecting-the-invisible-minimal-residual-disease-at-aacr-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-tissue-growth.webp?t=1777041759" type="image/jpeg" medium="image" fileSize="653690">
        <media:title type="plain">Illustration of a tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>AACR 2026: The age of agentic AI in oncology</title>
      <description>
        <![CDATA[New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of experimental compounds fail in clinical trials, underscoring the need for strategies that better capture human biology. Many of these techniques were showcased at the 2026 American Association for Cancer Research (AACR) annual meeting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730582</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730582-aacr-2026-the-age-of-agentic-ai-in-oncology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Abstract-digital-human-face-AI.webp?t=1776955679" type="image/jpeg" medium="image" fileSize="303061">
        <media:title type="plain">Illustration of human face that looks abstract and digital</media:title>
      </media:content>
    </item>
    <item>
      <title>Serif Biomedicines launches with modified DNA platform</title>
      <description>
        <![CDATA[Flagship Pioneering Inc. has announced the launch of Serif Biomedicines Inc., a biotechnology company pioneering modified DNA as a new class of medicines. Modified DNA brings together the best features of mRNA and gene therapy, while mitigating their limitations, by enabling medicines that are programmable, scalable, durable and redosable.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730555</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730555-serif-biomedicines-launches-with-modified-dna-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-DNA-double-helix-light-particles.webp?t=1776870451" type="image/jpeg" medium="image" fileSize="550567">
        <media:title type="plain">DNA double helix illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Kaleidoscope-like ‘engineered disorder’ expands imaging potential</title>
      <description>
        <![CDATA[A new metasurface design strategy that replaces rigid order with “engineered disorder” could significantly increase how many optical functions can be integrated into a single ultra-thin device without increasing size or complexity, according to a study published in <em>Nature Communications</em>. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730575</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730575-kaleidoscope-like-engineered-disorder-expands-imaging-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/kaleidoscope-pattern-art.webp?t=1776355120" type="image/jpeg" medium="image" fileSize="1285474">
        <media:title type="plain">Photo of kaleidoscope pattern</media:title>
      </media:content>
    </item>
    <item>
      <title>At AACR: Epigenetic fingerprints in metastases track tumor origin</title>
      <description>
        <![CDATA[When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on machine learning has identified DNA-methylation patterns that reveal the type of tissue a cancer comes from when the primary tumor cannot be found. This technique could help guide more specific treatments for patients with cancers of unknown primary, who today often receive broad, nontargeted chemotherapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730535</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730535-at-aacr-epigenetic-fingerprints-in-metastases-track-tumor-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-metastasis.webp?t=1776781708" type="image/jpeg" medium="image" fileSize="740126">
        <media:title type="plain">Illustration of metastatic cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Kaleidoscope-like ‘engineered disorder’ expands imaging potential</title>
      <description>
        <![CDATA[A new metasurface design strategy that replaces rigid order with “engineered disorder” could significantly increase how many optical functions can be integrated into a single ultra-thin device without increasing size or complexity, according to a study published in <em>Nature Communications</em>. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730425</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730425-kaleidoscope-like-engineered-disorder-expands-imaging-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/kaleidoscope-pattern-art.webp?t=1776355120" type="image/jpeg" medium="image" fileSize="1285474">
        <media:title type="plain">Photo of kaleidoscope pattern</media:title>
      </media:content>
    </item>
    <item>
      <title>New guidance advises on assessing safety of gene editing </title>
      <description>
        <![CDATA[The U.S. FDA’s latest draft guidance on gene therapies focuses on nonclinical studies using next-generation sequencing-based methods and bioinformatics to evaluate safety risks associated with off-target editing and loss of genome integrity in human gene-edited products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730446</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730446-new-guidance-advises-on-assessing-safety-of-gene-editing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-editing-CRISPR.webp?t=1599848770" type="image/png" medium="image" fileSize="484156">
        <media:title type="plain">Gene editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>More of everything as Amazon moves into AI-driven drug R&amp;D</title>
      <description>
        <![CDATA[Amazon is extending the reach of its “everything store” into drug R&D with the launch of an artificial intelligence-powered Bio Discovery business. The company has compiled a catalogue of 40-plus foundation models that have been trained on extensive biology datasets and are able to generate and evaluate drug molecules in silico. For now, this covers antibodies only, but it is intended to move into other modalities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730445</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730445-more-of-everything-as-amazon-moves-into-ai-driven-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Amazon-Bio-Discovery-4-14.webp?t=1776201314" type="image/jpeg" medium="image" fileSize="234848">
        <media:title type="plain">Amazon Bio Discovery AI-powered application</media:title>
        <media:description type="plain">The Amazon Bio Discovery AI agent helps scientists set up and run AI-powered drug discovery workflows. Credit: www.aboutamazon.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Financing at Vivatides to advance extrahepatic RNA therapeutics</title>
      <description>
        <![CDATA[Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic RNA delivery technologies. Proceeds from the financing will be used to further advance the company’s extrahepatic delivery platform and accelerate pipeline programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730327</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730327-financing-at-vivatides-to-advance-extrahepatic-rna-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline. At the start of the biotech industry, progress was slow. Between 1983 and 1995, the U.S. FDA approved an average of two biologics each year. Now, biologics have taken the lead by the smallest of margins, accounting for 50.1% of drugs in development at the start of 2026, according to the <em>Pharma Annual Review 2026</em>, published by Pharmaprojects, a firm that tracks global pharma R&D.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730343</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730343-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation (TIBI), could enable personalized glaucoma therapy, avoiding poor patient adherence to their prescribed regimen and eliminating the need for bulky electronic devices. Animal models tolerate it well and, although the load is concentrated at the edges of the lens, it is still unknown how it could affect visual acuity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730276</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730276-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation, could enable personalized glaucoma therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730149</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730149-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen to use Alloy Therapeutics’ Anticlastic ASO platform</title>
      <description>
        <![CDATA[Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730189</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730189-biogen-to-use-alloy-therapeutics-anticlastic-aso-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Dectisomes show potent activity against high-priority fungal pathogens</title>
      <description>
        <![CDATA[In previous work, researchers from the University of Georgia developed liposomes loaded with antifungal drugs and coated with the carbohydrate recognition domains of mouse dectin-1 and/or dectin-2, called Dectisomes. The murine Dectisomes efficiently bound and killed pathogenic fungi in vitro and in mouse disease models. In a new study, the team aimed to explore how to potentially move Dectisomes into the clinic with human dectin orthologues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730167</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730167-dectisomes-show-potent-activity-against-high-priority-fungal-pathogens</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Mucorales-mucormycosis-black-fungus.webp?t=1706630288" type="image/jpeg" medium="image" fileSize="196888">
        <media:title type="plain">Colony of Mucorales grown on petri dish with microscopic illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Tippingpoint raises seed financing to target epigenetic protein interfaces</title>
      <description>
        <![CDATA[Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730061</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730061-tippingpoint-raises-seed-financing-to-target-epigenetic-protein-interfaces</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Chromatin-compaction.webp?t=1775055876" type="image/jpeg" medium="image" fileSize="405741">
        <media:title type="plain">Chromatin compaction</media:title>
      </media:content>
    </item>
    <item>
      <title>Rybodyn raises funding to decode the dark proteome</title>
      <description>
        <![CDATA[Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729878</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729878-rybodyn-raises-funding-to-decode-the-dark-proteome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Health-research-body-molecules.webp?t=1743605757" type="image/jpeg" medium="image" fileSize="735256">
        <media:title type="plain">Art concept for medical research</media:title>
      </media:content>
    </item>
    <item>
      <title>PerturbAI emerges from stealth with an atlas full of data</title>
      <description>
        <![CDATA[PerturbAI has emerged from stealth mode with the release of the world’s largest in vivo CRISPR atlas as described in a preprint on <em>Biorxiv</em>. The study profiled over 7.7 million cells from the brains of 74 mice with different cellular knockouts of 1,947 disease-associated genes. The San Francisco-based company’s Perturb-seq platform combines CRISPR perturbations with single nucleus RNA sequencing to look at gene expression.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729875</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729875-perturbai-emerges-from-stealth-with-an-atlas-full-of-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Artificial-Intelligence-chip-digital-brain.webp?t=1774451411" type="image/jpeg" medium="image" fileSize="1001421">
        <media:title type="plain">Illustration of a computer chip with a brain on it</media:title>
      </media:content>
    </item>
    <item>
      <title>New E3 ligase atlas aims to expand degrader drug discovery</title>
      <description>
        <![CDATA[An international team led by Australia’s Walter and Eliza Hall Institute (WEHI) has created the first authoritative atlas for a class of enzymes that regulate almost every cellular process in the human body. The new atlas identifies 672 high-confidence E3 ligases and provides a new reference framework for disease biology and targeted protein degradation research.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729853</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729853-new-e3-ligase-atlas-aims-to-expand-degrader-drug-discovery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/WEHI-E3ome-Atlas-03-24-2026.webp?t=1774367730" type="image/jpeg" medium="image" fileSize="297208">
        <media:title type="plain">Illustration of the E3-ome atlas</media:title>
        <media:description type="plain">The organization and distribution of the landmark “E3-ome” atlas. The new compendium has resolved more than 18 years of inconsistencies within the scientific community. Credit: WEHI</media:description>
      </media:content>
    </item>
    <item>
      <title>Kyorin licenses Ube drug candidates</title>
      <description>
        <![CDATA[Kyorin Pharmaceutical Co. Ltd. and Ube Corp. have entered into a license agreement for novel drug candidates discovered by Ube.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729791</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729791-kyorin-licenses-ube-drug-candidates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/drug-development-research.webp?t=1618519686" type="image/png" medium="image" fileSize="696743">
        <media:title type="plain">Illustration of pill being analyzed</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA, NIH mark milestones toward reducing animal testing </title>
      <description>
        <![CDATA[In what the U.S. FDA has dubbed a milestone move toward fewer animal studies in drug development, the agency published a draft guidance to help sponsors validate new approach methodologies that can bring safe, effective drugs to market sooner based on human-centric data rather than starting off with nonclinical animal pharmacology and toxicology data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729851</guid>
      <pubDate>Fri, 20 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729851-fda-nih-mark-milestones-toward-reducing-animal-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Lab-mouse-and-test-tubes.webp?t=1762873451" type="image/jpeg" medium="image" fileSize="612519">
        <media:title type="plain">Lab mouse and test tubes</media:title>
      </media:content>
    </item>
    <item>
      <title>Alloy Therapeutics and Abbvie partner on antibody platform</title>
      <description>
        <![CDATA[Alloy Therapeutics Inc. has entered into an agreement with Abbvie Inc. to develop a new antibody platform to discover antibodies against targets that are difficult to address with current technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729674</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729674-alloy-therapeutics-and-abbvie-partner-on-antibody-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/antibodies-lab-research.webp?t=1717686528" type="image/jpeg" medium="image" fileSize="266442">
        <media:title type="plain">Lab glassware and antibodies art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Digital model simulates the first fully functioning living cell</title>
      <description>
        <![CDATA[Entering a cell and watching its entire inner machinery at work, how DNA is copied, how proteins are assembled, or how it splits in two, has been, for decades, an impossible dream. Now, scientists at the University of Illinois have recreated everything that happens inside a cell at molecular scale in an unprecedented computational model. Syn3A is the first 4D digital cell, capable of combining time and space to simultaneously represent all the internal processes that drive the life cycle of a minimal prokaryotic organism.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729644</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729644-digital-model-simulates-the-first-fully-functioning-living-cell</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Digital-Cell-half-half-ribopart-dnabd-ptns-rnas-03-13-26.webp?t=1773672243" type="image/jpeg" medium="image" fileSize="1101579">
        <media:title type="plain">A simulated cell in the early stages of division.</media:title>
        <media:description type="plain">A simulated cell in the early stages of division. Left half shows membrane (green cubes) and ribosomes (yellow/purple) interwoven through in the cell’s chromosome (red). Right side shows all the proteins (grey) and RNA (orange) inside the cell with a small cutaway to show a second copy of the cell’s chromosome (blue). Credit: Graphic by Zane Thornburg. From Thornburg, Z.R. et al. Cell 2026, March 9. doi: 10.1016/j.cell.2026.02.009. Licensed under CC BY 4.0.</media:description>
      </media:content>
    </item>
    <item>
      <title>Enodia acquires Sec61 assets from Kezar Life Sciences</title>
      <description>
        <![CDATA[Enodia Therapeutics SAS has acquired Kezar Life Sciences Inc.’s assets from its Sec61-based discovery and development program, including clinical-stage KZR-261. Insights from Kezar’s Sec61-based programs will further strengthen Enodia’s core focus on Sec61-driven selectivity for targeting protein degradation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729665</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729665-enodia-acquires-sec61-assets-from-kezar-life-sciences</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
    <item>
      <title>Three pediatric brain cancer types share a pineal gland origin</title>
      <description>
        <![CDATA[Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729642</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729642-three-pediatric-brain-cancer-types-share-a-pineal-gland-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-Pineal-gland.webp?t=1773154224" type="image/jpeg" medium="image" fileSize="214692">
        <media:title type="plain">Illustration of brain cross-section showing the pineal gland</media:title>
      </media:content>
    </item>
    <item>
      <title>Synthetic peptide and CAR-A each clear amyloid-β in Alzheimer’s</title>
      <description>
        <![CDATA[If one could sweep the brain clean and send the toxic substances that drive neurodegeneration to the recycling bin, perhaps one could treat Alzheimer’s disease. Researchers at the Chinese Academy of Sciences propose a new therapeutic strategy that uses synthetic peptides that bind to amyloid-β (Aβ) and direct it toward lysosomes. In addition, researchers at the Washington University School of Medicine in St. Louis have genetically modified astrocytes in vivo to express chimeric antigen receptors (CARs) that recognize and phagocytose Aβ plaques.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729577</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729577-synthetic-peptide-and-car-a-each-clear-amyloid-in-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Amyloid-plaques-nerve-cells-illustration.webp?t=1773070036" type="image/jpeg" medium="image" fileSize="879449">
        <media:title type="plain">Illustration of amyloid plaques on neurons</media:title>
      </media:content>
    </item>
    <item>
      <title>Three pediatric brain cancer types share a pineal gland origin</title>
      <description>
        <![CDATA[Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729507</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729507-three-pediatric-brain-cancer-types-share-a-pineal-gland-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-Pineal-gland.webp?t=1773154224" type="image/jpeg" medium="image" fileSize="214692">
        <media:title type="plain">Illustration of brain cross-section showing the pineal gland</media:title>
      </media:content>
    </item>
    <item>
      <title>Synthetic peptide and CAR-A each clear amyloid-β in Alzheimer’s</title>
      <description>
        <![CDATA[If one could sweep the brain clean and send the toxic substances that drive neurodegeneration to the recycling bin, perhaps one could treat Alzheimer’s disease (AD). Researchers at the Chinese Academy of Sciences propose a new therapeutic strategy that uses synthetic peptides that bind to amyloid-β (Aβ) and direct it toward lysosomes. In addition, researchers at the Washington University School of Medicine in St. Louis have genetically modified astrocytes in vivo to express chimeric antigen receptors (CARs) that recognize and phagocytose Aβ plaques.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729411</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729411-synthetic-peptide-and-car-a-each-clear-amyloid-in-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Amyloid-plaques-nerve-cells-illustration.webp?t=1773070036" type="image/jpeg" medium="image" fileSize="879449">
        <media:title type="plain">Illustration of amyloid plaques on neurons</media:title>
      </media:content>
    </item>
    <item>
      <title>Alternative splicing strategy shows promise for Rett syndrome</title>
      <description>
        <![CDATA[A therapeutic strategy based on alternative splicing of the MECP2 gene could restore protein levels in Rett syndrome, a neurological disorder caused by mutations in that gene. Scientists at Baylor College of Medicine have successfully tested this approach both in vitro in neurons from Rett patients that produce some functional protein, correcting the altered gene expression and improving neuronal functions, and in vivo in mice.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729322</guid>
      <pubDate>Wed, 04 Mar 2026 07:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729322-alternative-splicing-strategy-shows-promise-for-rett-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/X-Chromosomes-with-DNA-genetic-mutations.webp?t=1772654484" type="image/jpeg" medium="image" fileSize="473365">
        <media:title type="plain">Illustration of X chromosomes with DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Digital pathology speeds diagnostics, but tends to take shortcuts to do so</title>
      <description>
        <![CDATA[Computational pathology, which assesses molecular-level features of diseases directly from tissue images (rather than testing the tissue via methods such as staining or sequencing) is making rapid strides.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729148</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729148-digital-pathology-speeds-diagnostics-but-tends-to-take-shortcuts-to-do-so</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Computational-Pathology-Fayyaz-Minhas-University-of-Warwick.webp?t=1772555477" type="image/jpeg" medium="image" fileSize="857272">
        <media:title type="plain">Whole slide image illustrating the detection of key histological structures such as glands and cells. </media:title>
        <media:description type="plain">Whole slide image illustrating the detection of key histological structures such as glands and cells. Credit: Fayyaz Minhas/University of Warwick</media:description>
      </media:content>
    </item>
  </channel>
</rss>
